“…Lipopolysaccharide extract (Chaignat et al, 2014) CF-ELISA LVS (BB IND 157) formalin-inactivated and sonicated bacteria (Koskela and Salminen, 1985) cELISA hare type B strain (NVF1) Lipopolysaccharide extract (Sharma et al, 2013) ICT NA Lipopolysaccharide extract (Micromun ® ) ( Splettstoesser et al, 2010) TAT, tube agglutination test; MAT, microagglutination tests; LAT, latex agglutination test; IFA, immunofluorescence assay; ELISA, enzyme-linked immunosorbent assay; CF-ELISA, complement-fixing ELISA; cELISA, competitive ELISA; ICT, immunochromatographic assay; LVS, live vaccine strain. (Koskela and Salminen, 1985) 50 (141)/none mainly IgM ≥10 85.1% NA Clinically typical + positive serology ≥80 67.4% NA MAT (Viljanen et al, 1983) 70 (70)/none mainly IgM ≥80 95.7% NA ≥4fold rise in MAT or ELISA titers (Helvaci et al, 2000) 205 (205)/none mainly IgM ≥80 94.1% NA CCF + positive culture (10) or MAT ≥ 1:20 ≥160 85% NA (Porsch-Ozcürümez et al, 2004) 50 (50)/50 (50) mainly IgM >16 100% 100% CCF + seroconversion ≥64 92% 100% (Maurin et al, 2011) 93 (129)/281 (287) mainly IgM ≥160 50.5% 99.3% CCF + positive culture or PCR, or MAT or IFA ≥ 160, or seroconversion or ≥4fold rise in antibody titers (Kiliçet al, 2012) 42 culture-confirmed mainly IgM ≥160 97.6% Positive culture (Sharma et al, 2013) 19 (34)/50 (50) mainly IgM ≥10 82.4% 100% ≥4fold rise in TAT or MAT titers (Yanes et al, 2018) 74 (122)/134 (134) mainly IgM ≥80 75.3% 98.5% CCF + positive culture or PCR, or seroconversion, or ≥4fold rise in antibody titers LAT (Rastawicki et al, 2015) 77/309 mainly IgM ≥25 98.7% 100% TAT and ELISA IFA (Porsch-Ozcürümez et al, 2004) 50 (50)/50 (50) all >80 100% 92% same as MAT >320 94% 100% (Maurin et al, 2011) 93 129 (Carlsson et al, 1979) 28 (28)/48 (48) all ≥500 units 96.4% 97.9% F. tularensis detection by culture or immunofluorescence (Viljanen et al, 1983) 70 ( 2011; Yanes et al, 2018). Indeed, a crucial point for the MAT is the choice of the cutoff titer.…”